Navigation Links
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round

AURORA, Colo., July 31 /PRNewswire/ -- Sierra Neuropharmaceuticals, Inc., a formulator of pharmaceuticals for direct-to-the-brain treatment of neurological diseases, announced a $21.5-million venture capital Series A financing. Co-leads in the funding were HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners. Other investors include High Country Venture and GC&H Investments LLC.

Sierra uses a proprietary drug development process that makes use of standard implantable pumps placed surgically under the skin which deliver drugs directly to the fluid around the brain via a catheter. The approach aims to help patients suffering from severe epilepsy, depression, schizophrenia and other neurological diseases who, until now, have had to treat their conditions by taking drugs orally. "Many current oral therapies are limited in their use due to severe side effects and possible toxicities," says Daniel Abrams, M.D., Sierra's founder, Chief Scientific Officer, and Acting CEO. "For patients, this means they may be denied access to medicines that could otherwise be of great benefit. Even for those drugs that can safely be taken orally, patients often have difficulty maintaining a proper pill regimen and may take only 50-80% of their required dosage. By reformulating existing pharmaceuticals and delivering them via an implanted device, better treatment and new options can be made available to patients."

It is estimated that more than 10 million people in the United States and Europe suffer from severe neurological diseases not adequately treated by current oral medications and would benefit from a new approach. "We think Sierra's new approach offers a broad new pathway for treating neurological diseases," he says, "and an opportunity to enhance patient lives."

To further develop therapies and win FDA approval, Abrams says Sierra will work closely with both pump manufacturers and pharmaceutical companies. The latter, he says, could collaborate by developing life cycle regimes for existing drugs that will now be used at different dosing levels or, alternatively, by co-developing future CNS drugs that offer more therapeutic and commercial potential when delivered via implantable pump. Sierra's initial products will utilize off-patent drugs and are expected to enter clinical trials within the next year.

About Sierra Neuropharmaceuticals

Sierra Neuropharmaceuticals is a biopharmaceutical company focused on the development and commercialization of centrally-administered, small molecule therapeutics for the treatment of severe CNS diseases refractory to oral medications. These include epilepsy, schizophrenia, bipolar disorder, anxiety disorders and major depression. The company uses a proprietary drug development process to reformulate pharmaceuticals for direct delivery to the brain via standard implantable pumps.

About HealthCare Ventures

Founded in 1985, HealthCare Ventures LLC is a leading venture capital firm with offices in Cambridge, MA and Princeton, NJ, specializing in life science industry investing. Over the past 23 years, HealthCare Ventures has raised $1.6 billion in eight funds, and has invested in a total of 93 companies to date. Notable HealthCare Ventures' investments include such companies as Avidia, Dendreon Pharmaceuticals, Human Genome Sciences, LeukoSite, MedImmune, Novazyme, OraSure, Replidyne, Inc., Shire Pharmaceuticals, Tolerx, Verenium Corporation, and Vicuron Pharmaceuticals.

About Morgenthaler Ventures

Founded in 1968, Morgenthaler is a leading, national venture capital firm with offices in Menlo Park, CA (headquarters); Boston, MA; Cleveland, OH; and Boulder, CO; and with an investment focus on life sciences and information technology. Morgenthaler's life science investments, past and present, include such industry-leading companies as Avidia, CardioThoracic Systems, The Foundry, Morphotek, OncoMed, Orexigen, Perclose, and Xtent. Morgenthaler has a total of $2.5 billion under management. Its most recent fund, capitalized at $450 million, was raised in July of 2005. The firm ( has funded more than 300 companies over its 40-year history.

About Sequel Venture Partners

Sequel Venture Partners, based in Boulder, Colorado, provides venture funding for early stage technology businesses. Sequel manages $400 million in capital, and specializes in Healthcare, Internet and Enterprise IT, Clean Technology and Internet based services.

About High Country Venture

High Country Venture manages Colorado Fund I, which is a venture capital fund that invests in seed and early stage businesses in Colorado, focusing on Life Sciences (including biotechnology, agritechnology, and medical devices), information technology (including software and Internet companies) and retail. The mission of High Country Venture is to invest in the most promising and innovative early stage Colorado companies, help build them into strong, profitable businesses, and to capture that value creation through strategic financial decisions.

About GC & H Investments, LLC.

GC&H Investments, LLC, makes venture investments on behalf of lawyers with Cooley Godward Kronish LLP.

SOURCE Sierra Neuropharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NuVasive Completes Acquisition of Osteocel Biologics Business
2. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
3. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
4. Accuri Cytometers Completes $13 Million Series C Financing
5. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
6. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
7. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
8. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
9. Boston Scientific Completes Acquisition of CryoCor
10. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
11. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Post Your Comments:
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
Breaking Biology Technology:
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
Breaking Biology News(10 mins):